Chronic tolerance to recreational MDMA (3,4-methylenedioxymethamphetamine) or Ecstasy

Chronic tolerance to MDMA (Ecstasy) is well-documented: novice users typically take one tablet per session, regular users two to three, and experienced users may take ten to twenty-five tablets. Users often report reduced subjective effects with repeated use, leading to dose escalation and binge patterns such as stacking multiple tablets or boosting successive doses. Some experienced users snort or inject MDMA. Chronic tolerance and bingeing are statistically linked to higher rates of drug-related psychobiological problems. Neuroadaptive processes are involved, but evidence on hepatic and behavioral mechanisms is lacking. Animal research suggests serotonergic neurotoxicity from intensive dosing may contribute, potentially explaining parallel declines in efficacy, dose escalation, and rising problems. The underlying mechanisms remain unclear, with serotonergic neurotoxicity as a possible novel cause.

Study at a glance

Abstract

This review of chronic tolerance to MDMA (3,4-methylenedioxymetamphetamine) covers the empirical data on dosage escalation, reduced subjective efficacy and bingeing in recreational Ecstasy users. Novice users generally take a single Ecstasy tablet, regular users typically take 2-3 tablets, whereas the most experienced users may take 10-25 tablets in a single session. Reduced subjective efficacy following repeated usage is typically described, with many users subjectively reporting the development of tolerance. Intensive self-administration or bingeing is often noted by experienced users. This can comprise ‘stacking’ on several tablets together, and ‘boosting’ on successive doses over an extended period. Some experienced users snort Ecstasy powder nasally, whereas a small minority inject MDMA. Chronic tolerance and bingeing are statistically linked to higher rates of drug-related psychobiological problems. In terms of underlying mechanisms, neuroadaptive processes are certainly involved, but there is a paucity of evidence on hepatic and behavioural mechanisms. Further studies specifically designed to investigate chronic tolerance, involving low intermittent dose regimens, are required. Most animal research has involved intensive MDMA dosing regimens designed to engender serotonergic neurotoxicity, and this may comprise another underlying mechanism. If distal serotonin axon terminal loss was also developing in recreational users, it may help to explain why reducing subjective efficacy, dosage escalation and increasing psychobiological problems often develop in parallel. In conclusion, there is extensive evidence for chronic pharmacodynamic tolerance to recreational Ecstasy/MDMA, but the underlying mechanisms are currently unclear. Several traditional processes are probably involved, but one of the possible causes is a novel mechanism largely unique to the ring substituted amphetamine derivatives, namely serotonergic neurotoxicity.